Q3 2022 13F Holders as of 30 Sep 2022
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
226M
-
Number of holders
-
182
-
Total 13F shares, excl. options
-
106M
-
Shares change
-
+5.25M
-
Total reported value, excl. options
-
$1.15B
-
Value change
-
+$56.5M
-
Put/Call ratio
-
0.89
-
Number of buys
-
100
-
Number of sells
-
-59
-
Price
-
$10.80
Significant Holders of Allogene Therapeutics, Inc. - Common Stock (ALLO) as of Q3 2022
202 filings reported holding ALLO - Allogene Therapeutics, Inc. - Common Stock as of Q3 2022.
Allogene Therapeutics, Inc. - Common Stock (ALLO) has 182 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 106M shares
of 226M outstanding shares and own 47.03% of the company stock.
Largest 10 shareholders include TPG GP A, LLC (18.7M shares), BlackRock Inc. (8.21M shares), VANGUARD GROUP INC (7.16M shares), STATE STREET CORP (6.68M shares), PRICE T ROWE ASSOCIATES INC /MD/ (5.91M shares), Capital International Investors (5.31M shares), PRIMECAP MANAGEMENT CO/CA/ (4.89M shares), Woodline Partners LP (4.53M shares), EcoR1 Capital, LLC (4.49M shares), and JPMORGAN CHASE & CO (3.97M shares).
This table shows the top 182 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.